

County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 4th January 2018**

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
Aviptadil 25microgram/ Phentolamine 2mg solution for injection (Invicorp®)	✓ G+			<p>Aviptadil/phentolamine has been requested as a 3rd line option for the treatment of erectile dysfunction. It is of similar efficacy to alprostadil, although the study was poorly designed and may have overestimated efficacy. It causes less injection pain compared to alprostadil. Its anticipated place in therapy would be as an alternative to intracavernosal alprostadil in patients who have failed PDE5 inhibitors.</p> <p>Decision: The request for aviptadil/phentolamine (Invicorp®) was approved, subject to audit of use over next 6 months to demonstrate being used appropriately and as agreed. Place in therapy is as an alternative to intracavernosal alprostadil due to lack of efficacy or side-effects in patients who have failed PDE5 inhibitors.</p>

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Epiduo® 0.1% / 2.5% gel 1 g of gel contains: Adapalene 1 mg (0.1%) Benzoyl Peroxide 25 mg (2.5%)	✓ 			Requested as s an option for first line topical therapy for mild to moderate acne Vulgaris, or in combination with an oral antibiotic for patients with moderate to severe acne or first line treatment post-isotretinoin therapy. Decision: The request for Epiduo® gel was approved.
Budesonide 2mg/dose rectal foam (Budenofalk®)	✓ 			The proposal is to remove hydrocortisone foam (Colifoam®) from the formulary and replace with budesonide foam, and then making budesonide foam the 1st choice over prednisolone. Decision: The request for Budesonide 2mg/dose rectal foam (Budenofalk®) was approved as 1 st line rectal foam, and prednisolone rectal foam will be made 2 nd line.
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma	✓ 			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA479 Reslizumab for treating severe eosinophilic asthma	✓ 			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA480 Tofacitinib for moderate to severe rheumatoid arthritis	✓ 			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA481 Immunosuppressive therapy for kidney transplant in adults	✓ 			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA482 Immunosuppressive therapy for kidney transplant in children and young people	✓ 			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA483 Nivolumab for previously treated squamous non-small-cell lung cancer	✓ 			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA485 Sarilumab for moderate to severe rheumatoid arthritis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA486 Aflibercept for treating choroidal neovascularisation	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner.
TA487 Venetoclax for treating chronic lymphocytic leukaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA489 Vismodegib for treating basal cell carcinoma		✓		The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA490 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA491 Ibrutinib for treating Waldenstrom's macroglobulinaemia	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Northern (NHS) Treatment Advisory Group (N-TAG)				
Freestyle Libre	✓ R			The Northern (NHS) Treatment Advisory Group (NTAG) endorses the Regional Medicines Optimisation Committee (RMOC) position statement on the NHS prescribing of Freestyle Libre® Flash Glucose Monitoring System of the 1st November 2017. NTAG recommends Freestyle Libre® as an option for glucose monitoring in Type 1 diabetic patients only in the North East and Cumbria for patients who fulfil the RMOC criteria for the device. This device should not be prescribed in primary care and should only be initiated and prescribed by diabetic specialists.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
7) Appeals against earlier decisions by the APC				
None				
8) Miscellaneous decisions by the APC				
Hydrocortisone Acetate rectal foam 10% w/w (Colifoam®)				Decision: Agreed to remove from formulary and replace with budesonide rectal foam
Metformin sachets				Decision: Agreed to remove from formulary as product now discontinued.
Enoxaparin				There is now a biosimilar available. Decision: Agreed to list by brand on the formulary and that needs to be prescribed by brand to prevent prescribing/dispensing errors.
Hydromol Intensive 10% cream 30g and 100g	✓ Go			Decision: Agreed to add to formulary as 1 st line emollient for use in ichthyotic conditions otherwise considered a 3 rd line emollient.
Calmurid cream	✓ Go			Decision: Agreed to add to formulary as 1 st line emollient for use in ichthyotic conditions otherwise considered a 3 rd line emollient.
Ultrabase cream 50g, 200g and 500g	✓ Go			Decision: Agreed to add to formulary as 2 nd line emollient for use in teenage girls as it contains a rose fragrance which may aid compliance.
Minoxidil Foam		✗		Decision: Agreed to add to formulary as NOT APPROVED and add to DNP list as it is a cosmetic product and not a good all use of NHS resources. All other topical forms of minoxidil are blacklisted in the Drug Tariff. Patients can buy OTC or be prescribed privately.

The following guidelines were presented to and approved at the January 2018 meeting of the APC:

- Care Pathway for the Prescribing of Nutritional Supplements for Adults in CD&D – updated – approved subject to removal for information relating to free samples.
- Update to CD&D Drug Monitoring Document – Theophylline
- CD&D APC Emollient Prescribing Guideline for Dry Skin Conditions – updated Nov 2017
- Promazine De-prescribing Guidance

The following Green+ drug information leaflets were presented to and approved at the January 2018 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the January 2018 meeting of the APC:

- Nil